(vianews) - shares of poxel (cac 40: poxel.pa) dropped by a staggering 16.67% in 5 sessions from €0.86 to €0.72 at 16:07 est on friday, after two successive sessions in a row of losses. cac 40 is dropping 1.07% to €7,239.33, following the last session's upward trend.
poxel's last close was €0.76, 76.97% below its 52-week high of €3.30.
about poxel
poxel s.a., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. the company's lead product is twymeeg (imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in japan. it also develops pxl770, an adenosine monophosphate-activated protein kinase enzyme, which is in a phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (nash). poxel s.a. has a licensing agreement with enyo pharma s.a.s. for the development of farnesoid x receptor that is in phase 2a study for the treatment of hepatitis b and nash; and deuterx llc for the development of pxl065, a mitochondrial pyruvate carrier inhibitor, which is in a phase i clinical trial for the treatment of nash. the company was incorporated in 2009 and is headquartered in lyon, france.
earnings per share
as for profitability, poxel has a trailing twelve months eps of €-0.98.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -323.36%.moving average
poxel's value is way below its 50-day moving average of €0.98 and way under its 200-day moving average of €1.57.stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, poxel's stock is considered to be overbought (>=80).
more news about poxel (poxel.pa).